生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

交易中 04-09 12:02:43 EDT

1,134.65

+4.75

+0.42%

最高1,134.69	最低1,120.11	成交量6.89亿
今开1,129.90	昨收1,129.90	日振幅1.29%
总市值0.00	流通市值0.00	总股本0.00
成交额44.76亿	换手率--	流通股本0.00
市净率6.766315	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1134.6458,"timestamp":1775750563356,"preClose":1129.9001,"halted":0,"volume":689358412,"delay":0,"changeRate":0.0042,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":4.745605,"latestTime":"04-09 12:02:43 EDT","open":1129.8975,"high":1134.6907,"low":1120.1057,"amount":4475675664.889943,"amplitude":0.012908,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775764800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.766315,"peRate":-206.793478,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1147742148","title":"Alphaton Capital与Vertical Data达成4300万美元AI基础设施及融资合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1147742148","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147742148?lang=zh_cn&edition=full","pubTime":"2026-04-09 21:12","pubTimestamp":1775740366,"startTime":"0","endTime":"0","summary":"Alphaton Capital宣布与Vertical Data建立价值4300万美元的人工智能基础设施与融资合作伙伴关系。此次合作将整合双方在AI技术领域的资源优势，共同推进高性能计算基础设施的部署与创新。通过战略协同，双方计划在数据处理、算法优化及算力网络建设方面开展深度合作，为人工智能产业链提供更高效的底层支持。Alphaton Capital将依托其在另类投资领域的专业经验，为Vertical Data的AI基础设施扩展提供结构化融资解决方案。此次合作标志着资本市场与AI技术融合的进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104489368","title":"Akari Therapeutics参与虚拟投资者访谈，探讨与药明合联战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1104489368","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104489368?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:51","pubTimestamp":1775739103,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC日前参与了题为“这意味着什么”的虚拟投资者访谈活动，重点讨论了该公司与药明合联（WuXi XDC）达成的战略合作伙伴关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137777119","title":"Zentalis Pharmaceuticals宣布选定Azenosertib单药疗法400毫克每日一次（5:2方案）作为治疗周期蛋白E1阳性铂类耐药卵巢癌的关键研究剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1137777119","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137777119?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:01","pubTimestamp":1775736069,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals, LLC（纳斯达克代码：ZNTL）正式公布，其研发的Azenosertib单药疗法将以每日一次400毫克、采用用药五天休两天的给药方案，作为针对周期蛋白E1阳性铂类耐药卵巢癌患者开展关键性临床研究的确定剂量。这一决定基于前期临床试验数据，旨在优化疗效与安全性的平衡，为后续注册研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161492576","title":"ARS Pharmaceuticals Inc：Northland Capital 首次覆盖给予“跑赢大盘”评级，目标价25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161492576","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161492576?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:47","pubTimestamp":1775735233,"startTime":"0","endTime":"0","summary":"Northland Capital 近日宣布对 ARS Pharmaceuticals Inc 启动研究覆盖，并给予“跑赢大盘”的积极评级。该机构同时设定了25美元的目标股价，显示出对公司未来增长潜力的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183344206","title":"Invivyd公布Revolution项目进展 推进潜在首创及最优麻疹单抗候选药物Vms063用于治疗与预防","url":"https://stock-news.laohu8.com/highlight/detail?id=1183344206","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183344206?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:04","pubTimestamp":1775732653,"startTime":"0","endTime":"0","summary":"生物技术公司Invivyd, Inc.宣布，其Revolution项目取得重要进展，正加速推进新型麻疹单克隆抗体候选药物Vms063的研发。该药物具备成为同类首创及最优疗法的潜力，旨在用于麻疹的治疗与预防。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108680007","title":"Kymera Therapeutics宣布吉利德科学行使选择权，获得口服Cdk2分子胶降解剂候选药物KT-200授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1108680007","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108680007?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:02","pubTimestamp":1775732525,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics, Inc.今日宣布，其合作伙伴吉利德科学已正式行使选择权，获得口服Cdk2分子胶降解剂开发候选药物KT-200的授权许可。这一决定标志着双方在创新肿瘤疗法合作中的重要里程碑。通过分子胶降解技术，KT-200旨在高效降解致病蛋白，为肿瘤治疗提供新机制。此次选择权的行使，不仅验证了Kymera Therapeutics在蛋白质降解领域的研发实力，也为吉利德科学扩充其肿瘤管线增添了重要资产。双方将继续推进该候选药物的后续开发工作，加速其向临床应用的转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108241653","title":"C4 Therapeutics与罗氏深化长期合作 签署新型降解剂-抗体偶联物研发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1108241653","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108241653?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:00","pubTimestamp":1775732419,"startTime":"0","endTime":"0","summary":"C4 Therapeutics宣布与罗氏集团达成战略拓展协议，双方将基于新型靶向蛋白降解技术平台，共同探索降解剂-抗体偶联物的开发路径。该合作标志着两家公司在肿瘤治疗领域长达数年的合作关系进入新阶段。根据协议框架，C4 Therapeutics将获得预付款及阶段性研发里程碑资金，具体金额未公开。降解剂-抗体偶联物技术有望通过抗体介导的靶向递送系统，提升蛋白降解剂在病变组织的富集效率。此次合作延续了双方自2020年以来的联合研发成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CCCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148847126","title":"IDEAYA Biosciences与阿斯利康达成临床合作 共同推进IDE849联合Imfinzi治疗小细胞肺癌研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148847126","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148847126?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:24","pubTimestamp":1775730286,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc于2026年4月8日宣布与阿斯利康制药达成临床合作协定。根据美国证券交易委员会披露文件，双方将针对IDEAYA研发的IDE849与阿斯利康的Imfinzi联合疗法，开展针对广泛期小细胞肺癌的临床评估。根据协议安排，IDEAYA将作为临床试验的申办方，主导研究推进；阿斯利康则负责提供其抗PD-L1抗体Imfinzi。此次与阿斯利康的强强联合，有望加速该药物在难治性肿瘤领域的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","SG9999001176.SGD","LU2108987350.USD","LU0784384876.USD","LU0029864427.USD","LU1989772840.SGD","LU0949170772.SGD","LU0011850046.USD","LU1019634622.SGD","BK4139","LU2133065610.SGD","LU0266013472.USD","LU1880407132.USD","LU2324357040.USD","SGXZ57979304.SGD","LU0857590862.USD","LU0920783379.SGD","LU2468319806.SGD","LU0310799852.SGD","LU1153584641.USD","LU0784385170.HKD","LU1170363599.USD","IE00BJT1NW94.SGD","LU0827474353.SGD","LU0496365809.HKD","LU0128525929.USD","LU1989771016.USD","LU0575583348.USD","LU0757432116.USD","LU2089283258.USD","LU1078025761.USD","LU2023251221.USD","LU2293690249.USD","LU1496350502.SGD","LU2089284900.SGD","LU1061106388.HKD","LU0960981461.USD","LU0882574055.USD","SG9999001176.USD","LU1496350171.SGD","LU0738911758.USD","LU1003077747.HKD","LU1323610961.USD","LU0122379950.USD","LU0114720955.EUR","IE00B2B36J28.USD","SG9999013999.USD","LU2125909247.SGD","LU0976567544.SGD","LU1119994496.HKD","LU1084165304.USD","LU1267930813.SGD","LU1291159041.SGD","IE0034235188.USD","LU0128525689.USD","LU0171293334.USD","LU1267930227.SGD","LU0345777659.USD","BK5011","LU1023059063.AUD","LU2125909593.SGD","IE0009355771.USD","LU2355687059.USD","IE00BJJMRZ35.SGD","LU1003076772.USD","LU0997586432.USD","LU1196032939.SGD","LU2539964713.USD","LU0920840948.USD","IE0002141913.USD","LU0289739699.SGD","LU0158827948.USD","LU0661504455.SGD","LU1046234339.USD","LU0203347892.USD","LU1153585028.USD","LU2114397693.USD","LU0211328371.USD","IE00B4R5TH58.HKD","LU2091194634.USD","LU0345777147.USD","LU0972486137.USD","LU2293690082.USD","LU0823399737.USD","LU0640478417.SGD","LU0949170426.SGD","LU1983299246.USD","LU1923622614.USD","LU1481599808.USD","LU1481600234.SGD","IE00B3T34201.USD","LU0553294199.USD","LU0526926950.USD","LU0784383803.USD","LU1057294990.SGD","LU1267930573.SGD","LU2112291526.USD","LU1064927863.SGD","LU1814569148.SGD","LU1019632923.USD","LU0211326755.USD","LU0047473722.SGD","IE00BFTCPJ56.SGD","LU0211326839.USD","LU0708994859.HKD","LU1261432733.SGD","LU2279689827.SGD","LU0047473722.EUR","LU1051770623.HKD","LU0203345920.USD","LU0889565080.SGD","LU0499090636.EUR","LU2089984988.USD","IE00BKPKM643.USD","LU0077335932.USD","LU0211327993.USD","LU1487256676.USD","LU0052756011.USD","LU0964806797.USD","LU1301847155.USD","LU0963555726.SGD","AZN.UK","LU0792757196.USD","LU1267930490.SGD","LU1015430645.USD","LU0545039389.USD","LU0957799991.USD","LU0310800379.SGD","LU1880407215.USD","LU1104425308.USD","LU0969580561.USD","IDYA","LU0432979614.USD","LU0823416689.USD","LU0889566641.SGD","LU0058720904.USD","LU0310800965.SGD","LU2433249047.HKD","LU0390134368.USD","LU0784385840.USD","LU1273509221.SGD","LU0997586515.USD","LU1989772923.USD","LU0887340254.USD","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166712162","title":"IDEAYA Biosciences推进Ide849针对Dll3上调实体瘤的全球一期临床试验——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1166712162","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166712162?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:07","pubTimestamp":1775729236,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences公司正在积极推进其候选药物Ide849针对Dll3上调实体瘤的全球一期临床试验。这一研发进展已通过美国证券交易委员会的文件正式披露。该试验旨在评估Ide849在Dll3表达上调的各类实体瘤患者中的安全性、耐受性及初步疗效。此次全球一期临床试验的推进，标志着IDEAYA Biosciences在精准肿瘤学领域的研究取得重要阶段性成果。公司将继续依托其深厚的靶向治疗研发平台，探索Ide849为特定患者群体提供新的治疗选择的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174843416","title":"IDEAYA Biosciences 达成协议 评估Ide849联合Imfinzi治疗广泛期小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1174843416","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174843416?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:07","pubTimestamp":1775729235,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences公司宣布，已签署一项临床合作协议，旨在评估其研发的候选药物Ide849与阿斯利康的Imfinzi（度伐利尤单抗）联合疗法，用于治疗广泛期小细胞肺癌（ES-SCLC）患者。\n该研究将探索这种联合疗法的安全性、耐受性及初步疗效，为后续的临床开发提供关键数据依据。广泛期小细胞肺癌是一种侵袭性强、治疗选择有限的恶性肿瘤，此项合作有望为该患者群体带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626183806","title":"数据：HYPE 财库公司 Hyperliquid Strategies Inc 近期增持 22 万枚 HYPE，价值约 858 万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626183806","media":"链捕手","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626183806?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:18","pubTimestamp":1775726339,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，自 3 月 19 日以来，Hyperliquid Strategies Inc 已购买 22 万枚 HYPE，价值约 858 万美元，当前仍持有 1.126 亿美元现金储备。\n\n目前，Hyperliquid Strategies Inc 共持有 1882 万枚 HYPE，价值约 7.38 亿美元。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2257601","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PURR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118743082","title":"万达生物制药启动Thetis研究：评估Nereus™预防GLP-1受体激动剂所致呕吐的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1118743082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118743082?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:46","pubTimestamp":1775681177,"startTime":"0","endTime":"0","summary":"万达生物制药宣布正式启动名为\"Thetis研究\"的临床试验，该试验旨在评估其创新药物Nereus对GLP-1受体激动剂引发的呕吐症状的预防效果。这项研究将针对使用GLP-1受体激动剂治疗时出现胃肠道不良反应的患者群体，探索Nereus在控制药物相关性呕吐方面的潜在疗效。若试验结果积极，Nereus有望成为首款专门针对GLP-1类药物相关呕吐症状的预防性疗法，为全球数百万相关患者提供新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136789265","title":"TuHURA生物科学公司与H.C. Wainwright & Co.达成市场发售协议 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1136789265","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136789265?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:35","pubTimestamp":1775680540,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司已与H.C. Wainwright & Co.正式签署市场发售协议，相关细节已通过美国证券交易委员会文件公开披露。该协议标志着公司在资本市场的战略布局取得新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126354007","title":"MacroGenics Inc. 将依据修订后方案招募新受试者，并引入额外风险缓解措施","url":"https://stock-news.laohu8.com/highlight/detail?id=1126354007","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126354007?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:32","pubTimestamp":1775680323,"startTime":"0","endTime":"0","summary":"MacroGenics Inc. 宣布，其临床试验方案已获修订，新方案纳入了额外的风险缓解措施。依据更新后的研究方案，公司计划开始招募新的参与者加入该项研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110254167","title":"Phio制药公司与H.C. Wainwright签订市场发行协议，2026年4月8日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1110254167","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110254167?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:18","pubTimestamp":1775679495,"startTime":"0","endTime":"0","summary":"Phio制药公司已与H.C. Wainwright达成一项市场发行协议，并于2026年4月8日向美国证券交易委员会提交了相关文件。该协议的签署标志着公司融资策略的重要进展，为未来业务拓展提供了资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160534690","title":"AVITA Medical项目获美国卫生与公众服务部联邦资金全额或部分资助","url":"https://stock-news.laohu8.com/highlight/detail?id=1160534690","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160534690?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:18","pubTimestamp":1775679494,"startTime":"0","endTime":"0","summary":"AVITA Medical Ltd. (RCEL) 宣布其研发项目已获得美国卫生与公众服务部（HHS）的联邦资金支持，资助形式为全额或部分拨款。这一资金注入将助力公司推进其在再生医学领域的创新技术开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130120729","title":"Avita Medical Ltd. 获签为期十年、价值高达2550万美元的Barda协议，强化美国烧伤应急准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1130120729","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130120729?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:11","pubTimestamp":1775679073,"startTime":"0","endTime":"0","summary":"Avita Medical Ltd. (RCEL) 已正式获得一项为期十年的合作协议，该协议由美国生物医学高级研究与发展管理局（Barda）授予，潜在总价值高达2550万美元。此项重要合作旨在显著增强美国应对大规模烧伤紧急事件的准备能力。\n根据协议条款，Avita Medical 将负责确保其专有的再生医学技术平台——RECELL® 系统的持续研发、生产及供应保障。该协议不仅为公司的长期发展提供了稳定的资金支持，更凸显了其技术在国家级公共卫生应急储备中的关键战略价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196369375","title":"伊芙美尔医疗公布2026年第一季度初步未经审计业绩：产品销售额激增28.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196369375","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196369375?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:06","pubTimestamp":1775678780,"startTime":"0","endTime":"0","summary":"根据初步未经审计的销售结果，伊芙美尔医疗（ImmuCell）在2026年第一季度实现了产品销售额的显著增长，增幅高达28.4%。这一积极表现凸显了公司核心业务的强劲势头和市场需求的持续扩张。\n公司此次披露的初步数据，尽管尚未经过最终审计，但已清晰反映出其主打产品的市场竞争力与销售动能。销售额的大幅提升，为公司在2026财年的开局奠定了坚实的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ICCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119491727","title":"MAIA Biotechnology预计近期3300万美元融资将全额资助新型端粒靶向抗癌疗法关键三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1119491727","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119491727?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:02","pubTimestamp":1775653346,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology公司宣布，近期完成的3300万美元融资预计将完全覆盖其创新端粒靶向抗癌疗法的关键性三期临床试验费用。\n这项融资将确保公司核心研发项目获得充足资金支持，推动新型抗癌药物的临床进展。该疗法通过靶向端粒机制抑制癌细胞增殖，目前正处于临床试验的关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186367824","title":"Cue Biopharma将获得勃林格殷格翰合作与授权协议项下750万美元临床前里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1186367824","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186367824?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:00","pubTimestamp":1775649634,"startTime":"0","endTime":"0","summary":"Cue Biopharma, Inc. (以下简称Cue Biopharma) 宣布，其与勃林格殷格翰达成的合作与授权协议已达成一项重要临床前里程碑。根据协议条款，Cue Biopharma将因此获得750万美元的付款。\n该笔款项的支付标志着双方在特定药物研发项目上取得了关键进展，体现了合作关系的稳步推进。此次里程碑的达成不仅为Cue Biopharma带来了即时资金支持，也进一步验证了其技术平台在药物发现阶段的潜力。\n双方将继续推进合作项目的后续开发工作，致力于将创新疗法推向市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0033},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.0352},{"period":"1year","weight":0.3616},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}